Shahzad became a member of the board at Speciality European Pharma in February 2009. He was appointed Chairman in February 2011.
Shahzad is a General Partner at Advent Venture Partners, a venture capital company with a life science focus, which he joined in 1999. Prior to joining Advent, Shahzad spent six years practising medicine, before joining the London office of management consultants McKinsey & Company.
Shahzad gained an MA from Oxford University and an MD from Cambridge University. He subsequently specialised in interventional cardiology.
Patrick joined the board at Speciality European Pharma in March 2007 as Chief Financial Officer. He was appointed Chief Executive Officer in December 2010.
Prior to joining Speciality European Pharma, Patrick held the position of Chief Financial Officer at both Inpharmatica Limited (2001 – 2007), a chemogenomics company; and Phairson Medical Limited (1996 – 2001), a protein therapeutics discovery company. Prior to joining Phairson, Patrick spent more than ten years in the financial markets practice of Arthur Andersen in London.
Patrick is a qualified Chartered Accountant and an Economics graduate of the University of East Anglia.
Geoff joined the board of Speciality European Pharma in April 2006. Geoff was appointed to the position of Chief Executive Officer of the Company in December 2006 before resigning from that position in June 2010 to become a non-executive director of the Company.
Prior to joining Speciality European Pharma, Geoff was the Chief Executive Officer of Biofocus which he left in 2005 following its sale to Galapagos. Prior to this role, Geoff held a number of senior commercial positions with Elan, Roche and Xenova. Geoff started his career in sales and marketing with Smith and Nephew.
Tony joined the board at Speciality European Pharma in March 2006 as a non-executive Director of the company.
Tony is a seasoned healthcare professional with many years’ experience in the major functions of global pharmaceutical companies, latterly with Aventis in Paris. Tony is a non-executive director of a number of small healthcare companies, including Acpharma and Labopharm. Until its recent sale, Tony was a consultant to Amdipharm, a company he was instrumental in creating.
Kaasim joined the board at Speciality European Pharma in March 2011 and is a non-executive Director of the company.
Kaasim is a General Partner at Advent Venture Partners, a venture capital company with a life science focus, which he joined in 2005. Prior to joining Advent, Kaasim spent four years at Cutfield, Freeman & Co, a corporate finance boutique.
A qualified medical doctor, Kaasim holds an MB BS from the Royal Free & University College Medical School, London.